Merck Fosamax once-weekly patent upheld
Executive Summary
Merck Fosamax once-weekly dose will not face generic competition until 2019, under a ruling by the Wilmington, Del. federal court to uphold a method of use patent (no. 5,994,329) for the 35 mg and 70 mg strengths of the osteoporosis agent. Teva plans to appeal the decision; the company is also awaiting a ruling on its appeal of the same court's decision to uphold Merck's method of use patent covering the Fosamax (alendronate) once-daily products (1"The Pink Sheet" Nov. 11, 2002, In Brief)...
You may also be interested in...
Merck Fosamax patent upheld
Merck's Fosamax (alendronate) will not face generic competition until at least August 2007, following a decision by Wilmington, Del., federal court to uphold a method of use patent for the osteoporosis drug Nov. 4. Teva intends to appeal the decision...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.